CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-76927-0
Abstract: Parkinson's disease (PD) is a neurodegenerative disorder for which only symptomatic treatments are available. Repurposing drugs that target α-synuclein aggregation, considered one of the main drivers of PD progression, could accelerate the development of disease-modifying… read more here.
Keywords: synuclein; different synuclein; cmt targets; aggregates mitigating ... See more keywords